Protalix Biotherapeutics Inc
PLX1.890USD
+0.010+0.54%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
150.69MMarket Cap
24.01P/E TTM
More Details of Protalix Biotherapeutics Inc Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
Company Info
Ticker SymbolPLX
Company nameProtalix Biotherapeutics Inc
IPO dateSep 06, 2010
CEOMr. Dror Bashan
Number of employees207
Security typeOrdinary Share
Fiscal year-endSep 06
Address2 University Plaza
CityHACKENSACK
Stock exchangeEuronext Paris
CountryUnited States of America
Postal code07601
Phone12016969345
Websitehttps://protalix.com/
Ticker SymbolPLX
IPO dateSep 06, 2010
CEOMr. Dror Bashan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
303.00K
+74.14%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
303.00K
+74.14%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HIR Investments Ltd
5.91%
BlackRock Institutional Trust Company, N.A.
3.77%
Bashan (Dror)
2.86%
Renaissance Technologies LLC
2.03%
Geode Capital Management, L.L.C.
1.04%
Other
84.40%
Shareholders
Shareholders
Proportion
HIR Investments Ltd
5.91%
BlackRock Institutional Trust Company, N.A.
3.77%
Bashan (Dror)
2.86%
Renaissance Technologies LLC
2.03%
Geode Capital Management, L.L.C.
1.04%
Other
84.40%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.54%
Corporation
6.21%
Individual Investor
4.33%
Investment Advisor/Hedge Fund
3.78%
Hedge Fund
2.19%
Research Firm
0.32%
Pension Fund
0.14%
Venture Capital
0.09%
Bank and Trust
0.09%
Other
74.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
183
18.79M
23.60%
+3.26M
2025Q1
182
19.45M
25.30%
+4.26M
2024Q4
169
15.65M
21.26%
-1.03M
2024Q3
162
14.11M
19.17%
-5.41M
2024Q2
163
16.36M
22.25%
-4.44M
2024Q1
143
16.45M
23.43%
-4.40M
2023Q4
145
17.20M
24.67%
-3.21M
2023Q3
142
16.45M
24.08%
-6.46M
2023Q2
132
16.38M
24.76%
-4.13M
2023Q1
95
13.57M
27.32%
-11.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HIR Investments Ltd
4.71M
5.92%
--
--
Apr 30, 2025
Bashan (Dror)
2.28M
2.87%
--
--
Apr 30, 2025
Renaissance Technologies LLC
1.19M
1.49%
+70.95K
+6.35%
Mar 31, 2025
Northern Trust Global Investments Limited
683.30K
0.86%
-46.98K
-6.43%
Mar 31, 2025
Rubin (Eyal)
660.91K
0.83%
+90.91K
+15.95%
Apr 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
482.88K
0.61%
+482.88K
--
Mar 31, 2025
State Street Global Advisors (US)
296.10K
0.37%
+296.10K
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
